3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
36
Neoplasms
7
Neoplasm Metastasis
7
Endometrial Neoplasms
7
Ovarian Neoplasms
5
Triple Negative Breast Neoplasms
4
Breast Diseases
3
Brain Neoplasms
3
Sarcoma
2
Neoplasms by Site
2
Meningioma
2
Liposarcoma
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Kaposi
1
Retinoblastoma
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Osteosarcoma
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Interventions
elacestrant
1
abemaciclib
1
Tissue Banks
1
Temozolomide
1
RAD1901
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Central Nervous System Diseases
×
abemaciclib
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled